Please assess the completion status of the following clinical trial:

Trial Title: Phase IIIB Subcutaneous Abatacept Monotherapy Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Rheumatoid Arthritis~* Subjects Global Disease Assessment of greater than equal to 20 mm on a visual analog scale~* Discontinue all Biologics and Disease-modifying antirheumatic drugs (DMARDS) except for methotrexate~Exclusion Criteria:~* Received treatment with rituximab~* Subjects who have received treatment with immunoadsorbtion columns (such as Prosorba columns), mycophenolate mofetil (Cellcept®), cyclosporine A or other calcineurin inhibitors, or D-Penicillamine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subcutaneous (SC) Abatacept + Methotrexate (MTX) Cohort (Type: EXPERIMENTAL): In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants were also administered a stable MTX dose of greater than or equal to 10 mg once weekly for at least 4 weeks prior to first injection of SC abatacept.
- SC Abatacept Monotherapy Cohort (Type: EXPERIMENTAL): In the ST period, participants were administered a dose of 125 mg abatacept SC, once weekly, for 4 months. Participants did not receive MTX at screening i.e., MTX naive, or discontinued MTX due to lack of efficacy or tolerability at least 4 weeks prior to first injection of SC abatacept.

Based on this trial design, predict the completion outcome and termination type (if applicable).